{"disease":{"id":"drug-resistant-tuberculosis","name":"Drug resistant tuberculosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"bedaquiline","indication_name":"Drug resistant tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sirturo","generic_name":"bedaquiline","company_name":"Janssen Therap","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Diarylquinoline Antimycobacterial","quality_score":75,"revenue":"400","mechanism":"Sirturo works by blocking the potassium voltage-gated channel subfamily H member 2, which is essential for the survival of Mycobacterium tuberculosis bacteria."},{"drug_id":"pyrazinamide","indication_name":"Treatment of drug-resistant tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrazinamide","generic_name":"PYRAZINAMIDE","company_name":"Dava Pharms Inc","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Antimycobacterial [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"delamanid","indication_name":"Drug resistant tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltyba","generic_name":"delamanid","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"delamanid","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04119375","title":"Behavior Change and Digital Health Interventions for Improved TB Treatment Outcomes","phase":"NA","overall_status":"COMPLETED","enrollment_count":16146,"lead_sponsor_name":"Massachusetts Institute of Technology","has_results":false},{"nct_id":"NCT05671718","title":"Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment","phase":"NA","overall_status":"RECRUITING","enrollment_count":2944,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04147676","title":"Evaluation of Centralised TB Assay Solutions","phase":"","overall_status":"COMPLETED","enrollment_count":1050,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT05081401","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT05175794","title":"Triage Test for All Oral DR-TB Regimen (TRiAD Study)","phase":"","overall_status":"COMPLETED","enrollment_count":786,"lead_sponsor_name":"Centre for the AIDS Programme of Research in South Africa","has_results":false},{"nct_id":"NCT03827811","title":"Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis","phase":"","overall_status":"UNKNOWN","enrollment_count":625,"lead_sponsor_name":"University of Cape Town","has_results":false},{"nct_id":"NCT04421495","title":"Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":608,"lead_sponsor_name":"Beijing Chest Hospital","has_results":false},{"nct_id":"NCT03830671","title":"The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Beijing Chest Hospital","has_results":false},{"nct_id":"NCT01424670","title":"Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":511,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT04484129","title":"MDR-TB Close Contacts Tracing in China (TCCT Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT03822156","title":"Clinical Analysis of the Patients With Cavitary Pulmonary TB and Endobronchial TB in the PPM-UUH Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"University of Ulsan","has_results":false},{"nct_id":"NCT03604848","title":"NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB","phase":"NA","overall_status":"UNKNOWN","enrollment_count":488,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT00685360","title":"A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":481,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT07017803","title":"Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":460,"lead_sponsor_name":"Centre de Recherche Médicale de Lambaréné","has_results":false},{"nct_id":"NCT03338621","title":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":455,"lead_sponsor_name":"Global Alliance for TB Drug Development","has_results":true},{"nct_id":"NCT04062201","title":"Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":402,"lead_sponsor_name":"Wits Health Consortium (Pty) Ltd","has_results":false},{"nct_id":"NCT03867136","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04342598","title":"Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, India","phase":"","overall_status":"COMPLETED","enrollment_count":352,"lead_sponsor_name":"Harvard School of Public Health (HSPH)","has_results":false},{"nct_id":"NCT03896685","title":"Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":323,"lead_sponsor_name":"Médecins Sans Frontières, France","has_results":false},{"nct_id":"NCT04081077","title":"PRACTECAL-PKPD Sub Study","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":240,"lead_sponsor_name":"Medecins Sans Frontieres, Netherlands","has_results":false},{"nct_id":"NCT03266003","title":"An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment","phase":"NA","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT01071603","title":"Tuberculosis in China","phase":"","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03086486","title":"Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":181,"lead_sponsor_name":"Global Alliance for TB Drug Development","has_results":true},{"nct_id":"NCT04397536","title":"New Genomic Techniques and Management of Multidrug-resistant Tuberculosis","phase":"","overall_status":"UNKNOWN","enrollment_count":172,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02454205","title":"An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"University of Cape Town","has_results":false},{"nct_id":"NCT01212003","title":"Training Protocol on the Natural History of Tuberculosis","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03470233","title":"Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB","phase":"","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"Korea Otsuka Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02727582","title":"Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"University of Cape Town","has_results":false},{"nct_id":"NCT05007821","title":"Linezolid Dosing Strategies in Drug-Resistant TB","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":138,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03942354","title":"Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial","phase":"","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"Medecins Sans Frontieres, Netherlands","has_results":false},{"nct_id":"NCT04493671","title":"Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"Global Alliance for TB Drug Development","has_results":false},{"nct_id":"NCT07268664","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Beijing Chest Hospital","has_results":false},{"nct_id":"NCT07393438","title":"Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT06649721","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04717908","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS","phase":"NA","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04207112","title":"Economic Evaluation of New MDR TB Regimens","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Medecins Sans Frontieres, Netherlands","has_results":false},{"nct_id":"NCT07058233","title":"Oral Nutritional Supplementation and Weight Changes During Therapy in Malnourished Patients With Resistant Tuberculosis: A Clinical Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"RSUP Persahabatan","has_results":false},{"nct_id":"NCT07170800","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"WestVac Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT07191834","title":"A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Wuhan Pulmonary Hospital","has_results":false},{"nct_id":"NCT06224036","title":"Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"Beijing Chest Hospital","has_results":false},{"nct_id":"NCT04309656","title":"Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Global Alliance for TB Drug Development","has_results":true},{"nct_id":"NCT03575299","title":"Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":45,"lead_sponsor_name":"Zhinan Yin, Ph.D.","has_results":false},{"nct_id":"NCT01856634","title":"Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false},{"nct_id":"NCT01859923","title":"A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT01381757","title":"Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali","phase":"","overall_status":"TERMINATED","enrollment_count":34,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05526911","title":"A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Global Alliance for TB Drug Development","has_results":true},{"nct_id":"NCT04179500","title":"A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Global Alliance for TB Drug Development","has_results":true},{"nct_id":"NCT03057756","title":"Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance","phase":"","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Centre de Recherche Médicale de Lambaréné","has_results":false},{"nct_id":"NCT03000517","title":"PK of Levofloxacin in MDR-TB Patients","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT02274389","title":"A Prospective Patient Registry of Patients Exposed to Bedaquiline","phase":"","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false}],"total":50},"guidelines":[{"drug_id":"bedaquiline","guideline_body":"FDA label","recommendation":"SIRTURO is indicated as part of combination therapy in the treatment of adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid.","line_of_therapy":"2L","evidence_grade":"A","guideline_year":null},{"drug_id":"bedaquiline","guideline_body":"FDA label","recommendation":"SIRTURO is indicated as part of combination therapy in the treatment of adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid.","line_of_therapy":"2L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}